Total Price: $0.00
Contact Information
Recombinant Human uPAR Protein (His Tag)(Active)
SKU: PKSH031353-100
Recombinant Human uPAR Protein (His Tag)(Active)
| SKU # | PKSH031353 |
| Expression Host | HEK293 Cells |
Description
| Synonyms | CD87, MO3, Mo3, Monocyte activation antigen, PLAUR, U-PAR, UPAR, Urokinase Plasminogen Activator Surface Receptor, uPAR |
| Species | Human |
| Expression Host | HEK293 Cells |
| Sequence | Met 1-Arg 303 |
| Accession | Q03405-1 |
| Calculated Molecular Weight | 32.8 kDa |
| Observed Molecular Weight | 48 kDa |
| Tag | C-His |
| Bio-activity | Immobilized human uPAR at 5 μg/ml (100 μl/well) can bind biotinylated human UPA with a linear ranger of 40-1000 ng/ml. |
Properties
| Purity | > 98 % as determined by reducing SDS-PAGE. |
| Endotoxin | < 1.0 EU per μg of the protein as determined by the LAL method. |
| Storage | Generally, lyophilized proteins are stable for up to 12 months when stored at -20 to -80℃. Reconstituted protein solution can be stored at 4-8℃ for 2-7 days. Aliquots of reconstituted samples are stable at < -20℃ for 3 months. |
| Shipping | This product is provided as lyophilized powder which is shipped with ice packs. |
| Formulation | Lyophilized from sterile PBS, pH 7.4 Normally 5% - 8% trehalose, mannitol and 0.01% Tween 80 are added as protectants before lyophilization. Please refer to the specific buffer information in the printed manual. |
| Reconstitution | Please refer to the printed manual for detailed information. |
Background
Urokinase plasminogen activator (uPA) and/or its receptor (uPAR) are essential for metastasis, and overexpression of these molecules is strongly correlated with poor prognosis in a variety of malignant tumours. uPAR and uPA levels in both resected tumor tissue and plasma are of independent prognostic significance for patient survival in several types of human cancer. This system has classically been thought to drive tumor progression by mediating directed extracellular proteolysis on the surface of migrating or invading cells, and intervening with this proteolysis by targeting uPAR has been proposed to represent a novel approach for inhibiting tumor progression. uPAR, also known as PLAUR or CD87, has been implicated in the growth, metastasis, and angiogenesis of several solid and hemotologic malignancies. uPAR is a highly glycosylated, 55-60kDa integral membrane protein linked to the plasma membrane by a glycosylphosphatidylinositol (GPI) anchor. It is part of a cell surface system that also consists of the serine protease uPA and several specific inhibitors (plasminogen activator inhibitors 1 and 2). Additionally, the analysis of CD87 (urokinase-type plasminogen activator receptor - uPAR) expression has a potential role in the diagnostic or prognostic work-up of several hematological malignancies, particularly acute leukemia and multiple myeloma.